The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for TPG Asia VII SF Pte Ltd
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
TPG Asia VII SF Pte. Ltd, a Singapore-based private equity investor (not a promoter), sold 2,08,41,439 equity shares of Sai Life Sciences Ltd (face value ₹1 each) through an on-market transaction on June 20, 2025. This represents 10.00% of the company's total issued and paid-up equity share capital. After the sale, TPG's holding in Sai Life Sciences has come down from 5,15,48,272 shares (24.73%) to 3,07,06,833 shares (14.73%). The disclosure was filed on June 23, 2025 under SEBI's takeover regulations. No encumbrance or pledge-related activity is involved in this transaction.
This is a significant FII sell-down by one of the company's largest institutional shareholders, which may put short-term pressure on the stock. However, TPG continues to hold a substantial 14.73% stake, indicating it is a partial exit rather than a complete departure.